subsequently amplifies adaptive immune responses (53). Several cytokines, including interleukin-12 and type I interferon (IFN) secreted by dendritic cells, are involved in this immune process (54). As a result, synthetic ISS are attractive vaccine adjuvants that stimulate specific pathways critical to immune response regulation, resulting in minimal toxicity (55).
The ISS contained in HELIPSAV is a 22-mer phosphorothioate oligonucleotide, which is mixed with 20 µg of yeast (56). Excellent protective anti-HBs titers and good tolerability were noted in initials phase I studies (57). This was followed by a phase II comparative study using a licensed recombinant HBV vaccine among 99 healthy subjects aged 18 to 28 years. A greater proportion of HELIPSAV-treated recipients had a seroprotective anti-HBs levels at week 28 after when compared to those given recombinant HBV vaccine (100% and 64% respectively, p <0.001). HELIPSAV-treated group also had higher geometric mean titers than the recombinant vaccination group (2,074 versus 32 mIU/mL) (58).
The phase III results of HELIPSAV have been recently published (59). The first study, involving 2,415 healthy subjects aged 11 to 55 compared two doses of HELIPSAV versus three doses of recombinant HBV vaccination. HELIPSAV was able to achieve a higher seroprotective rates when compared to recombinant vaccine at the primary immunogenicity endpoint (95.1% and 81.1% respectively). Another phase III study investigated the efficacy of HELIPSAV in 420 healthy subjects aged 40 to 70 years and seronegative to HBsAg, anti-HBs and antibody to the hepatitis B core antigen (anti-HBc) (60). The seroprotective rate of HELIPSAV was significantly higher at week 9 involving 2,449 participants aged 40-70 found HELIPSAV to achieve a seroprotective rates of 94.6%, 94.7% and 95.6% in males, obese subjects and smokers respectively.
The seroprotective rates in the recombinant vaccine group among these three subject populations were only 67.8%, 65.4% and 65.3% respectively (61). In all studies, HELIPSAV was well-tolerated with similar safety profiles when compared to the recombinant vaccine. 
Other vaccine adjuvants
Other clinical trials in human subjects are summarized in Table 2. CPG 7909 is another CpG motif-based HBV vaccine adjuvant that has been found effective in phase I studies (63) and phase II studies involving HIV-infected subjects (64). Vaccine adjuvants systems that stimulate both cellular and antibody immune responses have been recently proven to be effective against malaria (65), and a similar system known as AS02, using monophosphoryl lipid A and Quillaja saponaria as vaccine adjuvants is also effective against HBV (66) , including in patients with renal insufficiency (67). There are also oral (49) and intranasal (68) HBV vaccines undergoing clinical evaluation.
potential to be approved for widespread use in the foreseeable future. These include novel nucleoside analogues, HBsAg release inhibitors, novel IFNs, anti-fibrotic agents and therapeutic vaccines (Table 3) .
Novel reverse transcriptase inhibitors
Given the established efficacy of nucleos(t)ide analogues in controlling CHB infection, there are several novel drugs that inhibit the reverse transcriptase involved in HBV DNA replication for both wild-type and drug-resistant HBV. These include besifovir and lagociclovir.
Besifovir (LB-80380)
Besifovir is an acyclic nucleotide phosphonate with its chemical structure similar to that of adefovir and tenofovir (81). It is a prodrug which is converted to LB-80331 through deacetylation in both the liver and intestine, then further oxidized to LB-80317, the active metabolite with antiviral effect towards HBV (Figure 1 ). LB-80317, unlike the prodrugs of adefovir and tenofovir, uses guanine instead of adenine as its base moiety, which contributes to an improved drug efficacy due to the lower intracellular concentrations of potentially competing guanine nucleotides compared to adenine nucleotides (82). Preclinical studies have found besifovir to show potent antiviral efficacy against both wild-type and drug-resistant HBV, with little reduction in mitochondrial DNA or lactic acid accumulation. Animal studies also found besifovir , when used in a similar dose as adefovir, to be 45 times less nephrotoxic (81). With its high potency, besifovir may find its place in the future as a third first-line agent, both for treatment-naïve as well as for lamivudine-resistant patients.
Lagociclovir
Lagociclovir valactate (also known as MIV-210) is a prodrug of 3'-fluoro-2', 3'-dideoxyguanosine (FLG). Animal studies have found FLG to be a potent inhibitor of hepadnavirueses, which includes HBV (87), and is active against lamivudine-, adefovirand entecavir-resistant HBV (88).
A woodchuck model involving different doses of lagociclovir found serum HBV DNA to decrease by more than 7 log after 10 weeks of therapy. There was also a 2 log decrease in intrahepatic covalently closed circular DNA (cccDNA). The reduction in HBV DNA, when compared to previous woodchuck models, was comparable to entecavir and better than lamivudine or adefovir (89). Phase I and II clinical studies are currently ongoing in Europe and Asia (80).
HBsAg release inhibitors
All currently available oral anti-HBV medication are nucleos(t)ide analogues, which target the activity of reverse transcriptase in viral replication. There has been research aimed at developing novel drugs targeting other areas in the biology of HBV. 
FG-3019 -novel antifibrotic agent
Hepatic fibrogenesis is a common pathway of liver damage seen in many chronic liver diseases, including CHB. The development of anti-fibrotic agents aimed at regressing liver fibrosis has thus aroused great interest. Fibrogenic mechanisms are dependent on the interplay of many pro-and anti-fibrotic cytokines, of which transforming growth factor beta (TGF-β) has been viewed as the -master‖ cytokine crucial for the advancement of fibrosis (112) . Important regulators of these cytokines are the connective tissue growth factors (CTGFs). Initially discovered in 1991 in the conditioned medium of human umbilical vein endothelial cells (113) , CTGF consists of four domains (Figure 3) , and up-regulates the majority of pro-fibrotic cytokines, including TGF-β, hence promoting hepatic fibrosis (114) . CTGF expression has been noted in hepatic stellate cells (HSCs), the main producers of extracellular matrix proteins related to fibrosis, in both experimental models and human patients (115, 116) . Hepatocytes Another study found combining a DNA vaccine containing recombinant interleukin-12 with lamivudine did not improve rates of virologic suppression (129) . DNA vaccines also fail to maintain virologic remission after cessation of nucleoside analogue therapy (130) .
One promising therapeutic vaccine currently undergoing clinical trials is DV-601.
This vaccine comprises of recombinant HBsAg and hepatitis B core antigen (HBcAg), and is engineered to stimulate a broad spectrum of T cells. In a phase I dose-escalation study, 14 CHB patients were started on concurrent entecavir and DV-601. A preliminary analysis showed all patients to have substantial reductions in both serum HBV DNA and HBsAg titers; HBeAg titers were also reduced in HBeAg-positive patients. Anti-HBs and antibody to the hepatitis B e antigen (anti-HBe) developed in higher dose groups. The vaccine was also well-tolerated (131).
The problem with therapeutic vaccines is that most CHB patients, especially those from Asia, Africa and certain Mediterranean countries, have been exposed to the virus since early childhood when the immune system is not yet fully matured. These carriers have also been exposed to large amounts of HBsAg for long periods of time.
With the virus forming cccDNA inside the hepatocyte nuclei as well as viral integration into the host genome, CHB patients might not mount a satisfactory immune response to therapeutic vaccination.
Future directions
CHB is now both preventable and treatable due to the remarkable advances achieved in the last three decades. Yet, eliminating and eradicating HBV totally remains HIV, human immunodeficiency virus. 
